Occurrence and Impact of Minor Histocompatibility Antigens' Disparities on Outcomes of Hematopoietic Stem Cell Transplantation from HLA-Matched Sibling Donors

Table 3

Patients characteristics (𝑛=62).

	Median ( range )	Quartiles
Age (years)
Donor	35 (14–60)	26–49
Recipient	38 (14–59)	28–47
Time from diagnosis to allo-HCT (years)	0.62 (0.24–12.91)	0.5–1.12
	𝑛	%
Sex
Donor
Male	32	51.6
Female	30	48.4
Recipient
Male	28	45.2
Female	34	54.8
Donor/recipient
Male/male	16	25.8
Female/female	18	29
Male/female	16	25.8
Female/male	12	19.4
Compatibility of ABO blood groups
Compatible	36	58.1
Minor incompatibility	8	12.9
Major incompatibility	14	22.5
Minor and major incompatibility	4	6.5
Diagnosis
AML	45	72.5
ALL	14	22.5
CML	1	1.61
MDS	1	1.61
NHL	1	1.61
Regimen
TBI + cyclophosphamide	12	19.35
Chemotherapy
Busulfan + cyclophosphamide	33	53.2
Treosulfan + fludarabine	13	20.96
Busulfan + fludarabine	2	3.22
Treosulfan + cyclophosphamide	2	3.22
Source of hematopoietic cells
Bone marrow	40	64.5
Peripheral blood	10	16.1
Bone marrow and peripheral blood	12	19.4
	Median (range)	Quartiles
Number of transplanted cells
Nucleated cells (NC) × 10𝑒8/kg	3.51 (0.12–72.15)	2.34–5.84
CD34(+) × 10𝑒6/kg	2.77 (0.95–10.50)	1.68–4.19
CD3(+) × 10𝑒7/kg	3.84 (0.20–46.90)	2.71–18.01
Time range of allo-HCT	01.2000–12.2008